JW (Cayman) Therapeutics Co Ltd
HKEX:2126

Watchlist Manager
JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Watchlist
Price: 2.71 HKD -2.52% Market Closed
Market Cap: 1.1B HKD

Gross Margin
JW (Cayman) Therapeutics Co Ltd

55.5%
Current
47%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.5%
=
Gross Profit
98.7m
/
Revenue
177.7m

Gross Margin Across Competitors

No Stocks Found

JW (Cayman) Therapeutics Co Ltd
Glance View

Market Cap
1.1B HKD
Industry
Biotechnology

JW (Cayman) Therapeutics Co. Ltd. operates as a clinical stage cell therapy platform company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-03. The firm is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The firm mainly conducts its businesses in the China market.

JW (Cayman) Therapeutics Co Ltd Intrinsic Value
HIDDEN
Show
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
55.5%
=
Gross Profit
98.7m
/
Revenue
177.7m
What is the Gross Margin of JW (Cayman) Therapeutics Co Ltd?

Based on JW (Cayman) Therapeutics Co Ltd's most recent financial statements, the company has Gross Margin of 55.5%.

Back to Top